Step-by-step pharmaceutical increased its capital by more than 6 million yuan, holding Nanjing huapai and entering the vaccine industry.

On January 17, step pharmaceutical announced that it planned to invest 61.1236 million yuan to increase the capital of Nanjing huapai biomedical Co., Ltd (hereinafter referred to as "Nanjing huapai") After the capital increase, it accounted for 54.4% of the registered capital of Nanjing huapai Pu Xiaoping, the company's director, Secretary of the board of directors, vice president, and Wang Baocai, the company's chief financial officer, made follow-up investment for the capital increase, with the amount of investment of RMB 1123600 and 112400 respectively Nanjing huapai was founded on November 8, 2018 with a registered capital of 50 million yuan, mainly engaged in biomedical engineering technology, biological product technology, pharmaceutical technology research, etc At present, Nanjing huapai Biotechnology Co., Ltd holds 8.94% equity, Wuxi daorun Jindu technology partnership (limited partnership) holds 30% equity, Wuxi Yidu technology partnership (limited partnership) holds 50% equity, Taizhou Yiwen huapai pharmaceutical partnership (limited partnership) holds 11.06% equity From its financial data, as of November 30, 2019, Nanjing huapai has no business income since its registration and establishment, and its net profit from January to November 2019 is - 18668600 yuan According to step Pharma, the capital increase of Nanjing huapai is to realize the development plan of step Pharma from sales type to scientific research type, from natural medicine to the whole pharmaceutical industry chain, from localization to globalization, and to enter the vaccine field After this capital increase, the registered capital of Nanjing huapai will increase to 112.4 million yuan Adorable adorable